2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-167898
    MeS-IMPY 955376-42-8 98%
    MeS-IMPY is a ligand of β-amyloid plaques. MeS-IMPY shows a high binding affinity to β-amyloid plaques extracted from Alzheimer's disease (AD) human brains or AD brain homogenates compared to IMPY (Ki=7.93 and 8.95 nM, respectively). [11C]MeS-IMPY is a potential radioligand for imaging β-amyloid plaques with positron emission tomography (PET).
    MeS-IMPY
  • HY-167905
    ATL444 867054-13-5 98%
    ATL444 is a adenosine receptor antagonist, with Ki values of 7.0, 2.5, 61.8, >1000 nM for rA1AR, rA2AAR, rA2BAR, rA3AR, respectively.
    ATL444
  • HY-167915
    Fosopamine hydrochloride 135962-35-5 98%
    Fosopamine hydrochloride serves as a dopamine receptor D agonist, making it a valuable tool for research on hypertension.
    Fosopamine hydrochloride
  • HY-167933
    (Rac)-Sabcomeline hydrochloride 133642-67-8 98%
    (Rac)-Sabcomeline ((Rac)-SB-202026) hydrochloride serves as an M1 receptor agonist, making it a valuable tool for research into Alzheimer's disease.
    (Rac)-Sabcomeline hydrochloride
  • HY-167936
    cis-AY 9944 1245-84-7 98%
    cis-AY 9944 is a cholesterol synthesis inhibitor, exhibiting anticonvulsant activity that influences the dynamics of spike and wave discharges in EEG recordings.
    cis-AY 9944
  • HY-167947
    (Rac)-Sabcomeline 149156-36-5 98%
    (Rac)-Sabcomeline ((Rac)-SB-202026) serves as an M1/M4 muscarinic agonist, making it a valuable tool in the exploration of neurological disorders, including schizophrenia.
    (Rac)-Sabcomeline
  • HY-168007
    NSC804515 98%
    NSC804515 is a lead compound for ATPase. NSC804515 can be used in cancer and nervous system related research.
    NSC804515
  • HY-168014
    5-Methylthio DMT 5102-11-4 98%
    5-Methylthio DMT (5-OMe DMT) is a tryptamine with psychoactivity.
    5-Methylthio DMT
  • HY-168021
    MAO-A/SERT-IN-1 3001361-38-9 98%
    MAO-A/SERT-IN-1 is an inhibitor of MAO-A/serotonin transporter (SERT). MAO-A/SERT-IN-1 can reduce SERT-mediated reuptake of 5-HT and has neuroprotective effects in cell inhibition models. MAO-A/SERT-IN-1 can improve depressive behavior in zebrafish and mice.
    MAO-A/SERT-IN-1
  • HY-168025
    VU6007496 2127101-85-1 98%
    VU6007496 is a highly selective and CNS penetrant M1 positive allosteric modulator (PAM). VU6007496 shows excellent pharmacokinetics (PK).
    VU6007496
  • HY-168028
    mGluR2 modulator 5 1639898-35-3 98%
    mGluR2 modulator 5 (Compound 11) is an orally active, selective mGluR2 negative allosteric modulator with an IC50 of 8.9 nM. Pharmacokinetic studies in rats show that mGluR2 modulator 5 can effectively cross the blood-brain barrier. It can modulate cognitive and neurological functions in mood disorders and is suitable for research in the field of neurodegenerative diseases.
    mGluR2 modulator 5
  • HY-168031
    AChE/BChE-IN-21 2756368-79-1 98%
    AChE/BChE-IN-21 is a histamine H3 receptor antagonist, calcium channel blocker, and acetylcholinesterase inhibitor. AChE/BChE-IN-21 exhibits neuroprotective activity against H2O2 and Aβ1-40, and can restore cognitive function in AD mice.
    AChE/BChE-IN-21
  • HY-168041
    LRRK2-IN-15 98%
    LRRK2-IN-15 is an LRRK2 inhibitor. The IC50 value for PBMC cells is 5 nM, and the IC50 value for BCRP is 1.5 μM. LRRK2-IN-15 can be used for research on Parkinson's disease.
    LRRK2-IN-15
  • HY-168051
    TLX agonist 2 98%
    TLX agonist 2 (compound 31) is a TLX agonist (EC50=0.1 μM; Kd=0.16 μM). TLX agonist 2 promotes TLX transcriptional activity and enhances the expression of TLX target genes by binding to TLX. TLX agonist 2 can be used in the study of neurodegenerative diseases.
    TLX agonist 2
  • HY-168052
    hAChE-IN-9 98%
    hAChE-IN-9 (compound 7i) is a selective inhibitor of human acetylcholinesterase (hAChE) with IC50 of 0.05 μM and 2.85 μM for AChE and BChE, respectively. hAChE-IN-9 modulates toxic Aβ oligomer forms into non-toxic ones and has antioxidant and neuroprotective effects against Aβ-induced toxicity. hAChE-IN-9 can be used for the study of Alzheimer's disease.
    hAChE-IN-9
  • HY-168060
    (8R)-8-Hydroxyepoxyboetirane A 98%
    (8R)-8-Hydroxyepoxyboetirane A is a neurogenic compound that interacts with PKC δ-C1B. (8R)-8-Hydroxyepoxyboetirane A binds to the PKC enzyme pocket via hydrogen bonds with Gly-253, Leu-251 and Thr242. (8R)-8-Hydroxyepoxyboetirane A induces NRG1 release and differentiation of NSC into neurons. (8R)-8-Hydroxyepoxyboetirane A is promising for research of neurological disorders.
    (8R)-8-Hydroxyepoxyboetirane A
  • HY-168068
    Res-Glu3 98%
    Res-Glu3 is the derivative of Resveratrol (HY-16561). Res-Glu3 mitigates the ROS accumulation, and exhibits neuroprotective efficacy against H2O2-caused cellular damage in PC12. Res-Glu3 exhibits antioxidant activity in rats ischemia reperfusion models.
    Res-Glu3
  • HY-168079
    GSK-3β inhibitor 21 98%
    GSK-3β inhibitor 21 (compound 44) is an ATP-competitive GSK-3β inhibitor (IC50=6.06 μM) with anti-amyloid aggregation and tau phosphorylation inhibitory activities. GSK-3β inhibitor 21 can be used in the study of Alzheimer's disease.
    GSK-3β inhibitor 21
  • HY-168096
    iNOs-IN-5 98%
    iNOs-IN-5 (Compound BN-4) is an inhibitor for iNOS with an IC50 of 0.1707 μM, and reduces NO levels in LPS (HT-D1056)-induced RAW264.7 cells. iNOs-IN-5 reduces the hypoxic injury stimulated ROS and lactate dehydrogenase expression, and exhibits anti-necrosis and anti-apoptosis efficacy. iNOs-IN-5 exhibits anti-cerebral ischemia and neuroprotective activities in SD rat models. iNOs-IN-5 is blood-brain barrier penetrable.
    iNOs-IN-5
  • HY-168167
    BuChE-IN-14 38455-99-1 98%
    BuChE-IN-14 is a novel compound that selectively inhibits acetylcholinesterase (AChE) activity. BuChE-IN-14 showed a concentration-dependent inhibitory effect on AChE in rat brain in vitro experiments. BuChE-IN-14 can increase the extracellular acetylcholine (ACh) concentration in the rat hippocampus and striatum at a certain dose. BuChE-IN-14 may help improve memory impairment caused by cholinergic dysfunction.
    BuChE-IN-14
Cat. No. Product Name / Synonyms Application Reactivity